Celyad Oncology is a clinical-stage biotechnology company centered on the development of chimeric antigen receptor (CAR) T-cell therapies for the treatment of cancer. This approach involves engineering patient or donor T cells to display a CAR that targets the immune cells to cancer cells via antigen–receptor binding.